CN110857440B - 重组人ⅱ型线粒体动力蛋白样gtp酶基因序列及其应用 - Google Patents

重组人ⅱ型线粒体动力蛋白样gtp酶基因序列及其应用 Download PDF

Info

Publication number
CN110857440B
CN110857440B CN201810968173.0A CN201810968173A CN110857440B CN 110857440 B CN110857440 B CN 110857440B CN 201810968173 A CN201810968173 A CN 201810968173A CN 110857440 B CN110857440 B CN 110857440B
Authority
CN
China
Prior art keywords
nucleic acid
sequence
cells
vector
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810968173.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN110857440A (zh
Inventor
李斌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuhan Niufusi Biological Technology Co ltd
Original Assignee
Wuhan Niufusi Biological Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201810968173.0A priority Critical patent/CN110857440B/zh
Application filed by Wuhan Niufusi Biological Technology Co ltd filed Critical Wuhan Niufusi Biological Technology Co ltd
Priority to EP19851390.5A priority patent/EP3851535A4/en
Priority to KR1020217008407A priority patent/KR102612148B1/ko
Priority to JP2021509904A priority patent/JP7285022B2/ja
Priority to AU2019323501A priority patent/AU2019323501B2/en
Priority to PCT/CN2019/102352 priority patent/WO2020038473A1/zh
Priority to BR112021002566-9A priority patent/BR112021002566A2/pt
Priority to CA3110153A priority patent/CA3110153A1/en
Priority to SG11202101236WA priority patent/SG11202101236WA/en
Priority to MX2021002135A priority patent/MX2021002135A/es
Publication of CN110857440A publication Critical patent/CN110857440A/zh
Application granted granted Critical
Publication of CN110857440B publication Critical patent/CN110857440B/zh
Priority to US17/182,903 priority patent/US11459584B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/03—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; catalysing transmembrane movement of substances (3.6.3)
    • C12Y306/03005—Zn2+-exporting ATPase (3.6.3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
    • C12Y306/05005—Dynamin GTPase (3.6.5.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201810968173.0A 2018-08-23 2018-08-23 重组人ⅱ型线粒体动力蛋白样gtp酶基因序列及其应用 Active CN110857440B (zh)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CN201810968173.0A CN110857440B (zh) 2018-08-23 2018-08-23 重组人ⅱ型线粒体动力蛋白样gtp酶基因序列及其应用
SG11202101236WA SG11202101236WA (en) 2018-08-23 2019-08-23 Gene sequence of recombinant human type ii mitochondrial dynein-like gtpase and uses thereof
JP2021509904A JP7285022B2 (ja) 2018-08-23 2019-08-23 組換えヒトＩＩ型ミトコンドリアダイニン様ＧＴＰａｓｅの遺伝子配列及びその使用
AU2019323501A AU2019323501B2 (en) 2018-08-23 2019-08-23 Recombinant human type II mitochondrial dynein-like GTPase gene sequence and application thereof
PCT/CN2019/102352 WO2020038473A1 (zh) 2018-08-23 2019-08-23 重组人ⅱ型线粒体动力蛋白样gtp酶基因序列及其应用
BR112021002566-9A BR112021002566A2 (pt) 2018-08-23 2019-08-23 sequência gênica da gtpase tipo dineína mitocondrial tipo ii humana recombinante e seus usos
EP19851390.5A EP3851535A4 (en) 2018-08-23 2019-08-23 RECOMBINANT HUMAN MITOCHONDRIAL DYNEIN-LIKE GTPASE TYPE II GENE SEQUENCE AND USE THEREOF
KR1020217008407A KR102612148B1 (ko) 2018-08-23 2019-08-23 재조합 인간 II형 미토콘드리아 다이네인-유사 GTPase의 유전자 서열 및 이의 용도
MX2021002135A MX2021002135A (es) 2018-08-23 2019-08-23 Secuencia génica de gtpasa similar a dineína mitocondrial de tipo ii humana recombinante y usos de esta.
CA3110153A CA3110153A1 (en) 2018-08-23 2019-08-23 Gene sequence of recombinant human type ii mitochondrial dynein-like gtpase and uses thereof
US17/182,903 US11459584B2 (en) 2018-08-23 2021-02-23 Gene sequence of recombinant human type II mitochondrial dynein-like GTPase and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810968173.0A CN110857440B (zh) 2018-08-23 2018-08-23 重组人ⅱ型线粒体动力蛋白样gtp酶基因序列及其应用

Publications (2)

Publication Number Publication Date
CN110857440A CN110857440A (zh) 2020-03-03
CN110857440B true CN110857440B (zh) 2021-02-19

Family

ID=69592310

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810968173.0A Active CN110857440B (zh) 2018-08-23 2018-08-23 重组人ⅱ型线粒体动力蛋白样gtp酶基因序列及其应用

Country Status (11)

Country Link
US (1) US11459584B2 (cg-RX-API-DMAC10.html)
EP (1) EP3851535A4 (cg-RX-API-DMAC10.html)
JP (1) JP7285022B2 (cg-RX-API-DMAC10.html)
KR (1) KR102612148B1 (cg-RX-API-DMAC10.html)
CN (1) CN110857440B (cg-RX-API-DMAC10.html)
AU (1) AU2019323501B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021002566A2 (cg-RX-API-DMAC10.html)
CA (1) CA3110153A1 (cg-RX-API-DMAC10.html)
MX (1) MX2021002135A (cg-RX-API-DMAC10.html)
SG (1) SG11202101236WA (cg-RX-API-DMAC10.html)
WO (1) WO2020038473A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110857440B (zh) 2018-08-23 2021-02-19 武汉纽福斯生物科技有限公司 重组人ⅱ型线粒体动力蛋白样gtp酶基因序列及其应用
CN111849998A (zh) * 2020-07-29 2020-10-30 武汉纽福斯生物科技有限公司 编码人卵黄状黄斑病蛋白1的核酸分子及其应用
CN117904156A (zh) * 2022-10-17 2024-04-19 武汉纽福斯生物科技有限公司 人线粒体动力蛋白样gtp酶及应用
WO2024226729A2 (en) * 2023-04-26 2024-10-31 Astellas Gene Therapies, Inc. Compositions and methods for opa1 gene therapy
CN117304293B (zh) * 2023-10-07 2025-08-08 浙江大学 一种鸡opa1抗原决定簇及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
AU7906691A (en) 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6596535B1 (en) 1999-08-09 2003-07-22 Targeted Genetics Corporation Metabolically activated recombinant viral vectors and methods for the preparation and use
WO2006073496A2 (en) 2004-07-30 2006-07-13 Targeted Genetics Corporation Recombinant aav based vaccine methods
ES2541771T3 (es) * 2005-05-03 2015-07-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Expresión de una proteína mitocondrial mediante un enfoque alotópico mejorado
WO2007134818A2 (en) * 2006-05-18 2007-11-29 Univ Muenchen L Maximilians Method for diagnosing mitochondrial dysfunction
CN102634527B (zh) * 2012-04-11 2013-11-06 华中科技大学同济医学院附属同济医院 重组人nadh脱氢酶亚单位4基因及其表达载体构建方法
CN116622704A (zh) * 2012-07-25 2023-08-22 布罗德研究所有限公司 可诱导的dna结合蛋白和基因组干扰工具及其应用
AR095983A1 (es) * 2013-04-03 2015-11-25 Aliophtha Ag Factores artificiales de transcripción para el tratamiento de enfermedades causadas por haploinsuficiencia de opa1
CN104450747B (zh) * 2014-09-23 2018-02-09 武汉纽福斯生物科技有限公司 用于治疗Leber遗传性视神经病变的重组腺相关病毒‑NADH脱氢酶亚单位4基因全长以及药剂
EP3289080B1 (en) * 2015-04-30 2021-08-25 The Trustees of Columbia University in the City of New York Gene therapy for autosomal dominant diseases
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
EP3548039B1 (en) * 2016-12-04 2023-07-19 Alavi Khorassani Moghadam, Marcel Victor Ribavirin for use in the treatment of a mitochondrial disease
JP7112414B2 (ja) 2017-02-08 2022-08-03 フリードリッヒ ミーシェー インスティトゥート フォー バイオメディカル リサーチ 網膜神経節細胞中の遺伝子の特異的発現のためのプロモーターｓｙｎｐ８８
CN111068071A (zh) * 2018-10-22 2020-04-28 武汉纽福斯生物科技有限公司 基因治疗Leber遗传学视神经病变
CN110857440B (zh) 2018-08-23 2021-02-19 武汉纽福斯生物科技有限公司 重组人ⅱ型线粒体动力蛋白样gtp酶基因序列及其应用

Also Published As

Publication number Publication date
US20210180086A1 (en) 2021-06-17
CA3110153A1 (en) 2020-02-27
JP7285022B2 (ja) 2023-06-01
CN110857440A (zh) 2020-03-03
AU2019323501A1 (en) 2021-02-25
SG11202101236WA (en) 2021-03-30
WO2020038473A1 (zh) 2020-02-27
JP2021533801A (ja) 2021-12-09
EP3851535A4 (en) 2022-12-14
AU2019323501B2 (en) 2023-08-03
US11459584B2 (en) 2022-10-04
EP3851535A1 (en) 2021-07-21
MX2021002135A (es) 2021-06-23
KR102612148B1 (ko) 2023-12-12
BR112021002566A2 (pt) 2021-06-22
KR20210049131A (ko) 2021-05-04

Similar Documents

Publication Publication Date Title
CN111621502B (zh) 视网膜劈裂蛋白的编码序列、其表达载体构建及其应用
ES2826384T3 (es) Terapia génica para trastornos oculares
US12467066B2 (en) Compositions and methods for treating retinal disorders
CN113025633B (zh) 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
KR102612148B1 (ko) 재조합 인간 II형 미토콘드리아 다이네인-유사 GTPase의 유전자 서열 및 이의 용도
US11970519B2 (en) Gene therapy vector for treating retinitis pigmentosa disease
US20100111911A1 (en) Mitochondrial nucleic acid delivery systems
JP2023539368A (ja) コドン最適化したｒｐｇｒｏｒｆ１５遺伝子およびその使用
WO2025247393A1 (zh) 用于治疗Prom1相关视网膜疾病的新型治疗药物
CN110699367B (zh) 编码人nadh脱氢酶亚单位4蛋白的核酸及其应用
AU2021337580B2 (en) Codon optimized REP1 genes and uses thereof
CN111926021B (zh) 重组人norrin胱氨酸结生长因子表达载体及其应用
WO2020077756A1 (zh) Nd4蛋白的编码序列及其应用
WO2020010491A1 (zh) 编码人nadh脱氢酶亚单位4蛋白的核酸及其应用
WO2020000641A1 (zh) 编码人nadh脱氢酶亚单位蛋白的核酸及其应用
CN111518813B (zh) 视紫红质的编码序列、其表达载体构建及其应用
EP4163375A1 (en) Expression vector of human nuclear factor e2-related factor 2 and application of expression vector
CN117904156A (zh) 人线粒体动力蛋白样gtp酶及应用
CN111909935B (zh) 重组人卷曲蛋白受体4(fzd4)的表达载体及其应用
HK40056038A (en) Recombinant human type ii mitochondrial dynein-like gtpase gene sequence and application thereof
WO2025026182A1 (zh) 融合多肽、包含其编码基因的表达盒、基因递送载体、药物组合物及用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20200303

Contract record no.: X2026980011809

Denomination of invention: Recombinant human type II mitochondrial dynamin-like GTPase gene sequence and its application

Granted publication date: 20210219

License type: Common License

Record date: 20260630